Jamie Horder

Summary

Publications

  1. ncbi Effects of 7 days of treatment with the cannabinoid type 1 receptor antagonist, rimonabant, on emotional processing
    Jamie Horder
    University Department of Psychiatry, Neurosciences Building, Warneford Hospital, Oxford, UK
    J Psychopharmacol 26:125-32. 2012
  2. ncbi Placebo, prozac and PLoS: significant lessons for psychopharmacology
    Jamie Horder
    Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK
    J Psychopharmacol 25:1277-88. 2011
  3. ncbi Acute administration of the cannabinoid CB1 antagonist rimonabant impairs positive affective memory in healthy volunteers
    Jamie Horder
    University Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, UK
    Psychopharmacology (Berl) 205:85-91. 2009
  4. ncbi Reduced neural response to reward following 7 days treatment with the cannabinoid CB1 antagonist rimonabant in healthy volunteers
    Jamie Horder
    University Department of Psychiatry, Warneford Hospital, Oxford, UK
    Int J Neuropsychopharmacol 13:1103-13. 2010

Detail Information

Publications4

  1. ncbi Effects of 7 days of treatment with the cannabinoid type 1 receptor antagonist, rimonabant, on emotional processing
    Jamie Horder
    University Department of Psychiatry, Neurosciences Building, Warneford Hospital, Oxford, UK
    J Psychopharmacol 26:125-32. 2012
    ..Investigating such effects could be useful in detecting adverse psychiatric effects of novel treatments...
  2. ncbi Placebo, prozac and PLoS: significant lessons for psychopharmacology
    Jamie Horder
    Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK
    J Psychopharmacol 25:1277-88. 2011
    ....
  3. ncbi Acute administration of the cannabinoid CB1 antagonist rimonabant impairs positive affective memory in healthy volunteers
    Jamie Horder
    University Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, UK
    Psychopharmacology (Berl) 205:85-91. 2009
    ..The anti-obesity drug and cannabinoid type 1 receptor antagonist, rimonabant, is associated with significant rates of depression and anxiety in clinical use...
  4. ncbi Reduced neural response to reward following 7 days treatment with the cannabinoid CB1 antagonist rimonabant in healthy volunteers
    Jamie Horder
    University Department of Psychiatry, Warneford Hospital, Oxford, UK
    Int J Neuropsychopharmacol 13:1103-13. 2010
    ..fMRI may be a useful method of screening novel agents for unwanted effects on reward and associated clinical adverse reactions...